Stocks · News reference
8-K filing — Lipocine Inc. (LPCN)
Filed: 2026-11-10 AccNo: 0001493152-26-050842 Size: 239 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Lipocine Inc. Reports Third Quarter 2026 Financial Results
Lipocine Inc. announced its financial results for the third quarter ended September 30, 2026, reporting a net loss of $0.7 million and total revenue of $2.3 million.
Nasdaq Falls Over 100 Points; US Crude Inventories Decline
U.S. stocks fell Wednesday, led by industrials. Crude inventories dropped unexpectedly, while Penguin Solutions and Lipocine surged; Caribou Biosciences
Canadian Approval Of Lipocine Drug Marks Progress for Oral Testosterone Options In Canada
Canada approves Lipocine’s TLANDO for adult males with testosterone deficiency. Partner Verity Pharma plans a launch by the end of 2026.
Dow Tumbles 350 Points; Constellation Brands Earnings Top Views
U.S. stocks fell Wednesday; Dow dropped 350 points. Energy rose, materials slid. Constellation beat estimates; oil gained while gold and silver fell.
Lipocine shares are trading higher after the company announced that Health Canada approved TLANDO for testosterone replacement therapy in adult males.